Bayer shares down 7% after U.S. court says it will review Monsanto case

Bayer shares down 7% after U.S. court says it will review Monsanto case


Logo and flags of Bayer AG are pictured outside a plant of the German pharmaceutical and chemical maker in Wuppertal, Germany.

Wolfgang Rattay | Reuters

Shares of German life sciences company Bayer fell nearly 7% on Wednesday, after a U.S. court said it would review a case alleging that exposure to products of the company’s Monsanto unit harmed individuals.

The Washington Supreme Court this week accepted a review of litigation against the German company over the impact of polychlorinated biphenyls (PCBs) exposure at the Sky Valley Education Center in Washington state, one of many related cases Bayer is fighting. Previously, an appeals court had overturned a $185 million award in the trial after finding flaws in the case in May, according to Reuters.

Bayer shares were 6.76% lower at 12:45 p.m. London time, putting the stock on course for its worst performance since March and extending a loss of 13% in the year to date. Shares had tumbled more than 30% last year amid challenges including ongoing litigation over the Monsanto unit and high net debt.

The company said in a statement Wednesday that there was “no basis for a different outcome on appeal,” and that it believed the Washington Court of Appeals’ decision had identified three errors in the case, including that testimony for the plaintiffs regarding PCB exposure lacked scientific validity.

Bayer argues the claims relate to industrial materials which Monsanto voluntarily ended manufacture of in 1977.

Bayer acquired U.S. agrichemical-maker Monsanto in 2018.

The deal has led to the company fighting myriad legal challenges in various U.S. courts over alleged negative health effects, including cancer, from exposure to Monsanto products including Roundup weed killer.

According to Reuters, around 125,000 charges have been brought against the product in the U.S., more than half of which had been resolved following a $10.9 billion settlement in 2020.

In September, the company secured a legal win when the 3rd U.S. Circuit Court of Appeals in Philadelphia found in its favor in a claim that Monsanto violated state law by failing to add a cancer warning to the Roundup label.

Stock Chart IconStock chart icon

hide content

Bayer share price.



Source

Why healthcare is the ‘ultimate hedge’ against an AI correction, according to Kepler Cheuvreux
World

Why healthcare is the ‘ultimate hedge’ against an AI correction, according to Kepler Cheuvreux

Key Points Talk of an AI bubble has grown since high-profile investor Michael Burry, known for predicting the housing meltdown ahead of 2008, revealed he is shorting AI players like Nvidia and Palantir. Healthcare, meanwhile, is recovering after a perfect storm, according to Kepler Cheuvreux analysts. The sector is also increasingly benefiting from AI adoption […]

Read More
Netflix to buy Warner Bros. film and streaming assets in  billion deal
World

Netflix to buy Warner Bros. film and streaming assets in $72 billion deal

Warner Bros. Studios in Burbank, California, US, on Wednesday, Nov. 26, 2025. Warner Bros. Jill Connelly | Bloomberg | Getty Images Netflix announced Friday it’s reached a deal to buy Warner Bros. Discovery, bringing a swift end to a dramatic bidding process that saw Paramount Skydance and Comcast also vying for the legacy assets. The […]

Read More
London’s answer to Wall Street gains momentum as major firms sign on
World

London’s answer to Wall Street gains momentum as major firms sign on

Skyscrapers in the Canary Wharf financial, business and shopping district in London, UK. Bloomberg | Bloomberg | Getty Images Visa is moving its European headquarters to London’s financial district, hot on the heels of an announcement by JPMorgan that it will build a landmark tower in an area considered to be the city’s answer to Wall Street. […]

Read More